Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: RYTM

Rhythm Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for RYTM. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.11

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 23:21 UTC.

What Rhythm Pharmaceuticals, Inc. does

This company develops biopharmaceutical treatments for rare neuroendocrine diseases, particularly focusing on medicines that target the MC4R pathway in the brain to treat hyperphagia and severe obesity. The company's lead product, IMCIVREE (setmelanotide), is already marketed in the United States, European Union, United Kingdom, Canada and several other countries for certain rare MC4R pathway diseases including Bardet-Biedl syndrome.

Summarized from Rhythm Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.11
Debt/equity0.91

Revenue, margins & earnings

FY2021: net loss $70M on revenue $3M$3MFY2021FY2022: net loss $181M on revenue $24M$24MFY2022FY2023: net loss $185M on revenue $77M$77MFY2023FY2024: net loss $261M on revenue $130M$130MFY2024FY2025: net loss $197M on revenue $190M$190MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-14
  • 2026-09-14President and CEOSale-1,817$190.0K
  • 2026-09-14President and CEOEmployee Stock Option (Right to Buy)Option exercise-50,000—
  • 2026-09-14President and CEOSale-30,746$3.15M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Rhythm Pharmaceuticals, Inc. do?

This company develops biopharmaceutical treatments for rare neuroendocrine diseases, particularly focusing on medicines that target the MC4R pathway in the brain to treat hyperphagia and severe obesity.

When did RYTM last file with the SEC?

Rhythm Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-25. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 23:21 UTC. This page is also available as JSON at /api/data?ticker=RYTM and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for RYTM and 5,000+ tickers.

Create a free account — keep RYTM
For your agent
GET /api/data?ticker=RYTM

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt